Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apatinib + docetaxel + S-1
- Development stage
- Unknown
- Lead developer
- Hengrui Therapeutics
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of apatinib, docetaxel, and S-1, being evaluated as a first-line treatment for metastatic gastric cancer. Apatinib is a small-molecule tyrosine kinase inhibitor that highly selectively inhibits vascular endothelial growth factor receptor 2 (VEGFR-2), thereby blocking tumor angiogenesis. Docetaxel is a cytotoxic chemotherapy agent that promotes microtubule assembly and inhibits disassembly, leading to cell cycle arrest. S-1 is an oral fluoropyrimidine combination (tegafur, gimeracil, and oteracil) that acts as an antimetabolite. This specific triple combination is being investigated in a Phase 2 clinical trial (NCT03154983) led by Dr. Zhou Fuxiang at Zhongnan Hospital of Wuhan University to improve progression-free survival in patients with metastatic gastric adenocarcinoma.
- Other names
- apatinib mesylate + docetaxel + S-1apatinib + docetaxel + tegafur-gimeracil-oteracil
02
Targets
TS (Thymidylate synthase)VEGFR2 (Vascular endothelial growth factor receptor 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on apatinib + docetaxel + S-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apatinib + docetaxel + S-1.